OBJECTIVE: Preclinical abuse liability assessment is an essential component of tobacco regulatory science. The goal of this project was to evaluate the relative abuse liability of smokeless tobacco products in rats using aqueous extracts of those products. These extracts provide exposure to an extensive range of nicotine and non-nicotine tobacco constituents as occurs in humans. METHODS: Rats were trained to self-administer either nicotine alone or extracts of Camel Snus or Kodiak smokeless tobacco at an equivalent nicotine unit dose. In Experiment 1, the relative reinforcing efficacy of these formulations was assessed in adults and adolescents using a progressive ratio schedule under limited-access conditions. In Experiment 2, relative reinforcing efficacy was assessed in adolescents under unlimited-access conditions using behavioral economic demand curve analysis. RESULTS: The reinforcing efficacy of nicotine formulations was higher in adolescents than adults, but no difference was observed between formulations in either age group. Similarly, there was no difference in elasticity of demand between formulations in adolescents. CONCLUSIONS: The present findings suggest that the abuse liability of these smokeless tobacco products is similar to nicotine alone, and that nicotine dose is the primary determinant of the reinforcing efficacy of systemic exposure to these products.
OBJECTIVE: Preclinical abuse liability assessment is an essential component of tobacco regulatory science. The goal of this project was to evaluate the relative abuse liability of smokeless tobacco products in rats using aqueous extracts of those products. These extracts provide exposure to an extensive range of nicotine and non-nicotinetobacco constituents as occurs in humans. METHODS:Rats were trained to self-administer either nicotine alone or extracts of Camel Snus or Kodiak smokeless tobacco at an equivalent nicotine unit dose. In Experiment 1, the relative reinforcing efficacy of these formulations was assessed in adults and adolescents using a progressive ratio schedule under limited-access conditions. In Experiment 2, relative reinforcing efficacy was assessed in adolescents under unlimited-access conditions using behavioral economic demand curve analysis. RESULTS: The reinforcing efficacy of nicotine formulations was higher in adolescents than adults, but no difference was observed between formulations in either age group. Similarly, there was no difference in elasticity of demand between formulations in adolescents. CONCLUSIONS: The present findings suggest that the abuse liability of these smokeless tobacco products is similar to nicotine alone, and that nicotine dose is the primary determinant of the reinforcing efficacy of systemic exposure to these products.
Authors: E C Donny; A R Caggiula; P P Rowell; M A Gharib; V Maldovan; S Booth; M M Mielke; A Hoffman; S McCallum Journal: Psychopharmacology (Berl) Date: 2000-09 Impact factor: 4.530
Authors: Mark G LeSage; Dan E Keyler; Don Shoeman; Donna Raphael; Gregory Collins; Paul R Pentel Journal: Pharmacol Biochem Behav Date: 2002-05 Impact factor: 3.533
Authors: Andrew C Harris; Laura Tally; Peter Muelken; Andrew Banal; Clare E Schmidt; Qing Cao; Mark G LeSage Journal: Drug Alcohol Depend Date: 2015-06-09 Impact factor: 4.492
Authors: Tracy T Smith; Matthew B Schaff; Laura E Rupprecht; Rachel L Schassburger; Deanne M Buffalari; Sharon E Murphy; Alan F Sved; Eric C Donny Journal: Drug Alcohol Depend Date: 2015-07-13 Impact factor: 4.492
Authors: Matthew R Costello; Daisy D Reynaga; Celina Y Mojica; Nurulain T Zaveri; James D Belluzzi; Frances M Leslie Journal: Neuropsychopharmacology Date: 2014-02-11 Impact factor: 7.853
Authors: A L Wong; S M McElroy; J M Robinson; S M Mulloy; F K El Banna; A C Harris; M G LeSage; A M Lee Journal: Drug Alcohol Depend Date: 2020-04-25 Impact factor: 4.492
Authors: John R Smethells; Andrew C Harris; Danielle Burroughs; Steven R Hursh; Mark G LeSage Journal: Drug Alcohol Depend Date: 2018-02-05 Impact factor: 4.492
Authors: Andrew C Harris; Peter Muelken; Yayi Swain; Mary Palumbo; Vipin Jain; Maciej L Goniewicz; Irina Stepanov; Mark G LeSage Journal: Drug Alcohol Depend Date: 2019-08-01 Impact factor: 4.492
Authors: Micah L Berman; Warren K Bickel; Andrew C Harris; Mark G LeSage; Richard J O'Connor; Irina Stepanov; Peter G Shields; Dorothy K Hatsukami Journal: Nicotine Tob Res Date: 2018-09-25 Impact factor: 4.244
Authors: Andrew C Harris; John R Smethells; Mary Palumbo; Maciej Goniewicz; Mark G LeSage Journal: Int J Environ Res Public Health Date: 2020-01-30 Impact factor: 3.390
Authors: Paul R Pentel; Michael D Raleigh; Mark G LeSage; Thomas Thisted; Stephen Horrigan; Zuzana Biesova; Matthew W Kalnik Journal: BMC Biotechnol Date: 2018-07-24 Impact factor: 2.563